Found: 9
Select item for more details and to access through your institution.
Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 7, p. 551, doi. 10.1007/s40261-023-01286-3
- By:
- Publication type:
- Article
Response to "Critical Analysis of Apixaban Dose Adjustment Criteria".
- Published in:
- Clinical & Applied Thrombosis/Hemostasis, 2022, v. 28, p. 1, doi. 10.1177/10760296221078841
- By:
- Publication type:
- Article
Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidates.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2019, v. 46, n. 6, p. 617, doi. 10.1007/s10928-019-09662-3
- By:
- Publication type:
- Article
Criteria to Reevaluate Anti-drug Antibody Assay Cut Point Suitability in the Target Population.
- Published in:
- AAPS Journal, 2020, v. 22, n. 2, p. 1, doi. 10.1208/s12248-019-0400-4
- By:
- Publication type:
- Article
Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 7, p. 3321, doi. 10.1111/bcp.15259
- By:
- Publication type:
- Article
A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Development and Qualification of a Drug‐Disease Modeling Platform to Characterize Clinically Relevant Endpoints in Type 2 Diabetes Trials.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 104, n. 4, p. 699, doi. 10.1002/cpt.998
- By:
- Publication type:
- Article
Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 9, p. 1358, doi. 10.1002/psp4.13015
- By:
- Publication type:
- Article
A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2018, v. 7, n. 9, p. 581, doi. 10.1002/psp4.12323
- By:
- Publication type:
- Article